David DeMartino - Nyxoah Chief Officer
| NYXH Stock | USD 7.97 0.43 5.70% |
Executive
David DeMartino is Chief Officer of Nyxoah
| Address | Rue Edouard Belin 12, Mont-Saint-Guibert, Belgium, 1435 |
| Phone | 32 10 22 23 55 |
| Web | https://www.nyxoah.com |
Nyxoah Management Efficiency
The company has return on total asset (ROA) of (0.2314) % which means that it has lost $0.2314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4969) %, meaning that it created substantial loss on money invested by shareholders. Nyxoah's management efficiency ratios could be used to measure how well Nyxoah manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.37. The current Return On Capital Employed is estimated to decrease to -0.43. As of now, Nyxoah's Other Assets are increasing as compared to previous years. The Nyxoah's current Other Current Assets is estimated to increase to about 4.8 M, while Total Assets are projected to decrease to under 94.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Muru Murugappan | Alcon AG | N/A | |
| Marna BronfenMoore | AngioDynamics | 57 | |
| JoAnne Alkire | Merit Medical Systems | N/A | |
| John CFA | West Pharmaceutical Services | N/A | |
| Terry MD | Alcon AG | N/A | |
| Kathy DePadua | West Pharmaceutical Services | N/A | |
| Hemanth Reddy | ResMed Inc | N/A | |
| Michele Polinsky | West Pharmaceutical Services | N/A | |
| Brian JD | Merit Medical Systems | 63 | |
| Elizabeth McCombs | Becton Dickinson and | 48 | |
| Laurie Miller | Haemonetics | 50 | |
| Ami Simunovich | Becton Dickinson and | N/A | |
| Mark Butler | Merit Medical Systems | N/A | |
| Carla Burigatto | Becton Dickinson and | N/A | |
| Nicholas JD | The Cooper Companies, | 50 | |
| Todd Friedman | ResMed Inc | N/A | |
| Kerri DiPietro | Haemonetics | N/A | |
| Antoinette Segreto | Becton Dickinson and | N/A | |
| Sarah Comstock | Merit Medical Systems | N/A | |
| Dr CFA | West Pharmaceutical Services | 57 | |
| Rajeev Varma | Haemonetics | N/A | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.23 |
Nyxoah Leadership Team
Elected by the shareholders, the Nyxoah's board of directors comprises two types of representatives: Nyxoah inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nyxoah. The board's role is to monitor Nyxoah's management team and ensure that shareholders' interests are well served. Nyxoah's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nyxoah's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeremy Feffer, VP Communication | ||
| Dorit Nahari, VP Operations | ||
| An Moonen, General Counsel | ||
| John Landry, Chief Officer | ||
| Inge Vanwittenbergh, Global Director | ||
| Francis Kim, Chief Officer | ||
| Mikaela Kirkwood, Corporate Manager | ||
| Loic Moreau, President International | ||
| Olivier Taelman, CEO Director | ||
| Remi Renard, Vice Access | ||
| David DeMartino, Chief Officer | ||
| Robert MBA, CoFounder Chairman | ||
| Jeyakumar Subbaroyan, Chief Officer | ||
| Bruno Onkelinx, Chief Officer | ||
| Maggie McGowan, Chief Officer |
Nyxoah Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nyxoah a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (11.83) % | ||||
| Current Valuation | 238.77 M | ||||
| Shares Outstanding | 37.43 M | ||||
| Shares Owned By Insiders | 41.70 % | ||||
| Shares Owned By Institutions | 35.36 % | ||||
| Number Of Shares Shorted | 46.56 K | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 56.31 X |
Currently Active Assets on Macroaxis
When determining whether Nyxoah offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nyxoah's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nyxoah Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nyxoah Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nyxoah. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Nyxoah Stock please use our How to Invest in Nyxoah guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nyxoah. If investors know Nyxoah will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nyxoah listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.166 | Quarterly Revenue Growth 0.297 | Return On Assets (0.23) | Return On Equity (0.50) |
The market value of Nyxoah is measured differently than its book value, which is the value of Nyxoah that is recorded on the company's balance sheet. Investors also form their own opinion of Nyxoah's value that differs from its market value or its book value, called intrinsic value, which is Nyxoah's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nyxoah's market value can be influenced by many factors that don't directly affect Nyxoah's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nyxoah's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nyxoah is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nyxoah's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.